References
- Manikandan P, Nagini S. Cytochrome P450 Structure, Function and Clinical Significance: A Review. Current Drug Targets. 2018; 19(1):38-54.
- Li-Wan-Po A, Girard T, Farndon P, et al. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br. J. Clin. Pharmacol. 2010; 69(3):222-230.
- Zhao M, Ma J, Li M et al. Cytochrome P450 Enzymes and Drug Metabolism in Humans. Int. J. Mol. Sci. 2021; 22(23):12808.
- Ingelman-Sundberg M. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2004; 369(1):89-104.
- Dorji PW, Tshering G, Na-Bangchang K. CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South-East and East Asian populations: A systematic review. J Clin Pharm Ther. 2019; 44:508-524
- Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002; 3(2):229-243.
- Hassani Idrissi H, Hmimech W, Khorb NE, et al. A synergic effect between CYP2C19*2, CYP2C19*3 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients. BMC Research Notes. 2018; 11(1):46.
- Brown SA, Pereira N. Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine. J. Pers. Med. 2018; 8(1):8.
- Riaz S, Muhammad Din S, Usman Tareen M, et al. Genetic Polymorphism of CYP2C19 in Pakistani Population. Iran J Pharm Res. 2019; 18(2):1097-1102.
- Ivanov HY, Grigorova D, Lauschke VM, et al. CYP2C19, and CYP2D6 Genotypes and Metabolizer Status Distribution in a Bulgarian Psychiatric Cohort. J Pers Med. 2022 Jul 21; 12(7):1187
- Nishida Y, Fukuda T, Yamamoto I, et al. CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. Pharmacogenetics. 2000; 10(6):567-570.
- Mo SL, Liu YH, Duan W, et al. Substrate Specificity, Regulation, and Polymorphism of Human Cytochrome P450 2B6. Current Drug Metabolism. 2009; 10(7):730-753.
- Langmia IM, Just KS, Yamoune S, et al. CYP2B6 Functional Variability in Drug Metabolism and Exposure Across Populations – Implication for Drug Safety, Dosing, and Individualized Therapy. Frontiers in Genetics. 2021; 12.
- Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenetics and Genomics. 2005; 15(1):1-5.
- Ciccacci C, Di Fusco D, Marazzi MC, et al. Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study. Eur J Clin Pharmacol 2013; 69(11):1909-1916.
- Zanger UM, Klein K. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Frontiers in Genetics. 2013; 4.
- Victorri-Vigneau C, Verstuyft C, Bouquié R, et al. Relevance of CYP2B6 and CYP2D6 genotypes to methadone pharma-cokinetics and response in the OPAL study. Br J Clin Pharmacol 2019; 85(7):1538-1543.
- Chiang YC, Wang RY, Huang CL, et al. Reduced dosing and liability in methadone maintenance treatment by targeting oestrogen signal for morphine addiction. J Cell Mol Med. 2017; 21(12):3552-3564.
- Aghabozorg Afjeh SS, Boshehri B, Hamednia S, et al. Investigating the CYP2B6 rs3745274 and rs3211371 polymorphisms in Methadone-Responder and Non-Responder Addicts in Iran. Iranian Biomedical Journal. 2021; 25(3):220-225.
- Kharasch ED, Regina KJ, Blood J, et al. Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism. Anesthesiology. 2015; 123(5):1142-1153.
- Dean L, Kane M. Clopidogrel Therapy and CYP2C19 Genotype. 2012 Mar 8 [updated 2022 Dec 1]. In: Pratt VM, Scott SA, Pirmohamed M, et al. editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012
- Alrajeh KY, Roman YM. The frequency of major CYP2C19 genetic polymorphisms in women of Asian, Native Hawaiian and Pacific Islander subgroups. Personalized Medicine. 2022; 19(4):327-339.
- Shuldiner AR, O‘Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009 Aug 26; 302(8):849-857
- Wang B, Wang J, Huang SQ, et al. Genetic Polymorphism of the Human Cytochrome P450 2C9 Gene and Its Clinical Significance. Current Drug Metabolism. 2009; 10(7):781-834.